New mRNA HIV vaccines enter early human testing

NCT ID NCT07569029

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-stage trial will test two experimental mRNA vaccines designed to teach the immune system to make antibodies that target HIV. About 42 adults with well-controlled HIV will receive the vaccines and then temporarily pause their regular HIV medication under close monitoring. The main goals are to check safety and see if the vaccines can trigger or boost specific immune responses against the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: two experimental mRNA HIV vaccines (DV700P-RNA and DV701B1.1-RNA)
What this could lead to: If successful, this could point toward a vaccine that helps the immune system better control HIV, potentially reducing the need for daily antiretroviral therapy.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The vaccines may not produce strong or lasting immune responses, and the planned pause in HIV medication carries risks of viral rebound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Alabama CRS (Site ID: 31788)
RECRUITING

Birmingham, Alabama, 35222, United States
Barranco CRS (Site ID: 11301)
NOT_YET_RECRUITING

Lima, 15063, Peru
Beth Israel Deaconess Medical Center / BIDMC VCRS (Site ID: 32077)
RECRUITING

Boston, Massachusetts, 02115, United States
Bridge HIV CRS (Site#: 30305)
NOT_YET_RECRUITING

San Francisco, California, 94102, United States
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site#: 30007)
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)
NOT_YET_RECRUITING

Bellavista, Provincia Constitucional del Callao, 07006, Peru
Columbia P&S CRS (Site#: 30329)
NOT_YET_RECRUITING

New York, New York, 10032, United States
Fundacion Huesped CRS (Site ID: 31957)
NOT_YET_RECRUITING

Buenos Aires, C1427CEA, Argentina
Penn Prevention CRS (Site#: 30310)
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19104, United States
San Miguel CRS (Site ID: 11302)
NOT_YET_RECRUITING

Lima, 15088, Peru
Seattle Vaccine and Prevention CRS (Site ID: 30331)
RECRUITING

Seattle, Washington, 98109, United States
Seke South CRS/30294 University of Zimbabwe -Clinical Trials Research Centre (UZ-CTRC)
NOT_YET_RECRUITING

Harare, Zimbabwe
Spilhaus CRS/30314 University of Zimbabwe -Clinical Trials Research Centre (UZ-CTRC)
NOT_YET_RECRUITING

Harare, Zimbabwe
The Hope Clinic of the Emory Vaccine Center CRS (Site #: 31440)
NOT_YET_RECRUITING

Decatur, Georgia, 30030, United States
The Ponce de Leon Center CRS (Site ID: 5802)
RECRUITING

Atlanta, Georgia, 30308, United States
University of Pittsburgh CRS (Site#: 1001)
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Vaccines to Prevent HIV Infection CRS (Site#: 31467)
NOT_YET_RECRUITING

Rochester, New York, 14642, United States
Vanderbilt Vaccine (VV) CRS (Site#: 30352)
NOT_YET_RECRUITING

Nashville, Tennessee, 37232, United States
Via Libre CRS (Site ID: 31909)
NOT_YET_RECRUITING

Lima, 15001, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.